close

Agreements

1 2 3 4 5 6 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-10-09 Iris Pharma (France) Keen Eye (France) artificial intelligence (AI) applications for bioimaging analysis ophtalmological diseases collaboration Ophtalmological diseases - Technology - Services Collaboration agreement
2018-10-09 ERS Genomics (Ireland) GenAhead Bio (Japan) CRISPR/Cas9 genome editing technology patents licensing Technology - Services Licensing agreement
2018-10-09 Ziopharm Oncology (USA - MA) Precigen (USA - MD) Sleeping Beauty licensing Cancer - Oncology Licensing agreement
2018-10-08 Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD) manufacturing platform for gene therapy programs manufacturing - bioproduction Rare diseases - Genetic diseases - Technology - Services Production agreement
2018-10-08 eTheRNA immunotherapies (Belgium) mRNA manufacturing facility opening of new premises Cancer - Oncology - Technology - Services Opening of new premises
2018-10-08 Vivebiotech (Spain) undisclosed European hospitals - undisclosed Norwegian company lentivirus cancers, undisclosed rare disease services contract Technology - Services Services contract
2018-10-08 Cytosen Therapeutics (USA - TX) member of the board of directors nomination Cancer - Oncology Nomination
2018-10-05 Oxford Biomedica (UK) Orchard Therapeutics (UK) lentiviral vectors for ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic disorders adenosine deaminase severe combined immunodeficiency (ADA-SCID), mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A), undisclosed follow-on indications. collaboration Rare diseases - Genetic diseases Licensing agreement
2018-10-05 Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) AAV1 neurotrophin 3 (NT-3) gene therapy Charcot-Marie-Tooth (CMT) neuropathies including CMT type 1A licensing Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement
2018-10-04 Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA)
  • ARO-HBV and up to three additional RNA interference (RNAi) therapeutics
hepatitis B licensing - research Infectious diseases Licensing agreement
2018-10-04 Horizon Discovery (UK) Celyad (Belgium) shRNA technology licensing Technology - Services Licensing agreement
2018-10-03 Boston Pharmaceuticals (USA - MA) Novartis (Switzerland) LYS228, IID572, MAK181 carbapenem-resistant enterobacteriaceae (CRE) infections, Pseudomonas infections licensing Infectious diseases Licensing agreement
2018-10-03 Boston Pharmaceuticals (USA - MA) GSK (UK) GSK3352589, GSK3008356, GSK3183475 and two undisclosed preclinical programs acne, irritable bowel syndrome with diarrhea (IBS-D) licensing Autoimmune diseases - Dermatological diseases - Digestive Diseases - Inflammatory diseases Licensing agreement
2018-10-03 Trovagene (USA - CA) Massachusetts Institute of Technology (MIT) (USA - MA) combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor licensing Cancer - Oncology Licensing agreement
2018-10-03 Cellular Biomedicine Group (China) National Cancer Institute (USA) next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology licensing Cancer - Oncology Licensing agreement
2018-10-02 Kite Pharma (USA - CA), a Gilead company (USA - CA) HiFiBiO Therapeutics (USA - MA) neoantigen-reactive T cell receptors (TCRs) for the treatment of various cancers research - licensing Cancer - Oncology Licensing agreement
2018-10-02 Cytosen Therapeutics (USA - TX) KBI Biopharma (USA - NC) Natural Killer (NK) cells bioproduction - manufacturing Cancer - Oncology - Technology - Services Production agreement
2018-10-01 Editas Medicine (USa - MA) senior vice president nomination Rare diseases - Genetic diseases - Ophtalmological diseases Nomination
2018-10-01 Melinta Therapeutics (USA - CT) Menarini (Italy) Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic Gram-negative organisms, infections due to susceptible strains of important designated gram-positive and gram-negative pathogens, including infections due to Acinetobacter species licensing - development - commercialisation Infectious diseases Licensing agreement
2018-10-01 KangStem Biotech (South Korea) MaSTherCell, (Belgium), a subsidiary of Orgenesis (USA - NY) Furestem-AD® manufacturing - bioproduction Technology - Services Production agreement